Sodium myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis in pressure overloaded mouse hearts
European Journal of Heart Failure · 12.03.2026 · 28 (Supplement_1)
DOI: 10.1093/ejhf/xuag034.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 12.03.2026. Verfasst von A Marino und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Our recent findings identify myo-inositol as a novel metabolite consistently elevated in patients with heart failure. It is specifically transported by the sodium/myo-inositol co-transporter-1 (SMIT1), a member of the sodium-glucose co-transporter (SGLT) family expressed in the heart. However, the underlying mechanisms by which myo-inositol and SMIT1 contribute to heart failure remain unclear. We aimed to determine the role of SMIT1 in left ventricular remodelling and its involvement in the progression to heart failure.
Methods
We used a model of pressure overload induced by transverse aortic constriction in wild type (WT) and SMIT1 deficient (Smit1-/-) mice. Cardiac structure and function were evaluated using contrast-enhanced microfocus computed tomography and echocardiography. The contribution of SMIT1 to molecular changes was assessed using immunoblotting, histological staining, and RNA-sequencing. In addition, we used primary cultures of adult mouse, neonatal and adult rat ventricular myocytes to investigate the molecular pathways influenced by SMIT1.
Results
We found that aortic banding fails to induce systolic dysfunction, cardiac hypertrophy and fibrosis in Smit1-/- mice, in contrast to WT controls. SMIT1 expression promotes cardiomyocytes hypertrophy through activation of the IP3/Ca++ signalling. Transcriptomic analysis revealed significant alteration in calcium effectors, including Carabin, a protein that inhibits the calcineurin/NFAT and Ras/ERK1/2 pathways. Accordingly, we demonstrated that Carabin is a SMIT1 downstream key mediator of the transcriptional reprogramming driving cardiac hypertrophy.
Conclusions
This work establishes SMIT1 as a critical driver of hypertrophy via calcium-dependent pro-hypertrophic signalling. The absence of SMIT1 protects against pressure overload-induced left ventricular remodelling, highlighting SMIT1 inhibition as a potential therapeutic target for preventing or treating pathological hypertrophy and heart failure.
Zitieren
APA
Marino, A., Cumps, J., Guilbert, L., Geiser, A., Ginion, A., Matos, F. D., Zuurbier, C. J., Lezoualch, F., Roderick, L. H., Bertrand, L., Horman, S., & Beauloye, C. (2026). Sodium myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis in pressure overloaded mouse hearts. European Journal of Heart Failure, 28(Supplement_1). https://doi.org/10.1093/ejhf/xuag034.034
Vancouver
Marino A, Cumps J, Guilbert L, Geiser A, Ginion A, Matos FD, et al. Sodium myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis in pressure overloaded mouse hearts. European Journal of Heart Failure. 2026;28(Supplement_1). doi:10.1093/ejhf/xuag034.034
BibTeX
@article{Marino2026,
author = {Marino, A and Cumps, J and Guilbert, L and Geiser, A and Ginion, A and Matos, F De and Zuurbier, C J and Lezoualch, F and Roderick, L H and Bertrand, L and Horman, S and Beauloye, C},
title = {Sodium myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis in pressure overloaded mouse hearts},
journal = {European Journal of Heart Failure},
year = {2026},
volume = {28},
number = {Supplement_1},
doi = {10.1093/ejhf/xuag034.034}
}
EUVIMED